Breaking News Instant updates and real-time market news.

RFIL

RF Industries

$3.45

0.1 (2.99%)

, CAL

Caleres

$29.09

0.69 (2.43%)

17:38
03/13/18
03/13
17:38
03/13/18
17:38

On The Fly: After Hours Movers

UP AFTER EARNINGS: RF Industries (RFIL), up 31.9%... Caleres (CAL), up 9.1%... Petiq (PETQ), up 7.4%... MongoDB (MDB), up 4.3%. ALSO HIGHER: Radiant Logistics (RLGT), up 5% after it announced a 5M share repurchase program... Trillium Therapeutics (TRIL), up 4.6% after its treatment of cutaneous T-cell lymphoma was granted orphan designation by the FDA. DOWN AFTER EARNINGS: Abraxas (AXAS), down 4.7%... Sientra (SIEN), down 4.4%. ALSO LOWER: Silicom (SILC), down 16.3% after it announced the cancelation of a contract awarded by a top-10 player... CatchMark (CTT), down 6.9% after it filed to sell 4.5M shares of common stock... Tintri (TNTR), down 3.2% after it named Thomas Barton CEO... Rapid7 (RPD), down 2.5% after it announced an offering of 2M shares of common stock for holders... Hilton Grand Vacations (HGV), down 1.8% after it offered 24.75M shares of common stock for holders.

RFIL

RF Industries

$3.45

0.1 (2.99%)

CAL

Caleres

$29.09

0.69 (2.43%)

PETQ

PetIQ

$22.81

-0.12 (-0.52%)

MDB

MongoDB

$37.86

-1.64 (-4.15%)

RLGT

Radiant Logistics

$3.81

-0.07 (-1.80%)

TRIL

Trillium Therapeutics

$7.60

-0.05 (-0.65%)

AXAS

Abraxas Petroleum

$2.36

0.04 (1.72%)

SIEN

Sientra

$10.03

-0.35 (-3.37%)

SILC

Silicom

$40.66

-17.9 (-30.57%)

CTT

CatchMark Timber

$13.61

-0.03 (-0.22%)

TNTR

Tintri

$4.35

-0.41 (-8.61%)

RPD

Rapid7

$27.52

0.31 (1.14%)

HGV

Hilton Grand Vacations

$45.80

-0.27 (-0.59%)

  • 13

    Mar

  • 13

    Mar

  • 13

    Mar

  • 13

    Mar

  • 13

    Mar

  • 13

    Mar

  • 14

    Mar

  • 14

    Mar

  • 14

    Mar

  • 29

    Mar

  • 11

    Apr

  • 15

    May

  • 14

    Mar

  • 14

    Mar

  • 15

    Mar

RFIL RF Industries
$3.45

0.1 (2.99%)

CAL Caleres
$29.09

0.69 (2.43%)

01/23/18
SUSQ
01/23/18
DOWNGRADE
SUSQ
Neutral
Caleres downgraded to Neutral from Positive at Susquehanna
01/23/18
SUSQ
01/23/18
DOWNGRADE
Target $33
SUSQ
Neutral
Caleres downgraded to Neutral at Susquehanna
As reported previously, Susquehanna analyst Sam Poser downgraded Caleres to Neutral from Positive. The analyst said the share price fairly reflects the company's progress with key brands and supply chain improvements. Poser raised his price target to $33 from $32 on Caleres shares.
05/30/17
SUSQ
05/30/17
UPGRADE
SUSQ
Positive
Caleres upgraded to Positive from Neutral at Susquehanna
12/19/17
WEDB
12/19/17
NO CHANGE
Target $33
WEDB
Outperform
Shoe Carnival price target raised to $33 from $27 at Wedbush
Wedbush analyst Christopher Svezia raised his price target for Shoe Carnival (SCVL) to $33 from $27 as he believes tax reform is likely to be signed into law. The analyst finds Shoe Carnival, Steven Madden (SHOO), Caleres (CAL), Foot Locker (FL), and Wolverine World Wide (WWW) as having the most upside to current share levels whereas DSW (DSW), Dick's Sporting (DKS), and Under Armour (UAA;UA) appear to have tax reform's impact priced into shares. He reiterates an Outperform rating on Shoe Carnival's shares.
PETQ PetIQ
$22.81

-0.12 (-0.52%)

11/20/17
JEFF
11/20/17
UPGRADE
Target $26
JEFF
Buy
PetIQ upgraded to Buy from Hold at Jefferies
Jefferies analyst Kevin Grundy upgraded PetIQ to Buy saying the recent pullback in shares provides an attractive entry point. In a non-deal roadshow, management conveyed a "high degree of confidence" in the company's outlook, Grundy tells investors in a research note. He believes the short thesis that has emerged "brings little new" information.
08/15/17
RHCO
08/15/17
INITIATION
Target $28
RHCO
Buy
PetIQ initiated with a Buy at SunTrust
SunTrust analyst William Chappell started PetIQ with a Buy rating and $28 price target. Increased customer penetration should drive "strong" growth over the next few years, the analyst contends.
08/15/17
RAJA
08/15/17
INITIATION
Target $26
RAJA
Outperform
PetIQ initiated with an Outperform at Raymond James
Raymond James analyst Joseph Altobello initiated PetIQ with an Outperform and a $26 price target saying the company is poised for double digit net sales and EBITDA growth.
08/15/17
08/15/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kratos Defense (KTOS) initiated with a Buy at Drexel Hamilton. 2. PetIQ (PETQ) was initiated with an Outperform at Raymond James, William Blair, and Oppenheimer, while being initiated with a Buy at SunTrust and a Hold at Jefferies. 3. Donnelley Financial Solutions (DFIN) initiated with a Neutral at JPMorgan. 4. Calyxt (CLXT) initiated with a Buy at Citi. 5. Ecolab (ECL) initiated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MDB MongoDB
$37.86

-1.64 (-4.15%)

02/14/18
NEED
02/14/18
UPGRADE
Target $34
NEED
Buy
MongoDB upgraded to Buy at Needham on valuation and 'fundamental checks'
As reported earlier, Needham analyst Jack Andrews upgraded MongoDB to Buy from Hold with a $34 price target. Andrews attributes the rating change to his recent research and fundamental checks, along with the "seasoning" of the post-IPO shares and a more attractive valuation. The analyst contends that the company's AGPL model is "more favorably and easier to scale than originally envisioned", adding that MongoDB can have less operating expenses and "justify the value proposition of its commercial versus open-source versions" to its customers. Based on its growth rate, Andrews says MongoDB should trade at a premium to its peers.
02/14/18
NEED
02/14/18
UPGRADE
NEED
Buy
MongoDB upgraded to Buy from Hold at Needham
01/23/18
NOMU
01/23/18
INITIATION
Target $30
NOMU
Neutral
MongoDB initiated with a Neutral at Nomura Instinet
Nomura Instinet analyst Christopher Eberle started MongoDB with a Neutral rating and $30 price target. The analyst is cautious on the shares given the "crowded field of competitors" in the database market and the company's significant burn-rate.
01/23/18
NOMU
01/23/18
INITIATION
Target $30
NOMU
Neutral
MongoDB initiated with a Neutral at Nomura Instinet
Nomura initiated MongoDB with a Neutral and $30 price target.
RLGT Radiant Logistics
$3.81

-0.07 (-1.80%)

TRIL Trillium Therapeutics
$7.60

-0.05 (-0.65%)

12/14/17
HCWC
12/14/17
NO CHANGE
Target $10
HCWC
Buy
Trillium price target raised to $10 from $7 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised his price target for Trillium Therapeutics to $10 saying the company presented "impressive" first results from the Phase 1 study of intratumoral TTI-621 for the treatment of relapsed or refractory mycosis fungoides. The analyst believes TTI-621 could become a "highly efficacious treatment." He reiterates a Buy rating on the shares.
07/17/17
HCWC
07/17/17
INITIATION
Target $7
HCWC
Buy
Trillium Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis started Trillium Therapeutics with a Buy rating and $7 price target. The analyst estimates that Trillium's lead product, TTI-621, which is currently being evaluated in Phase 1 and Phase 1b clinical studies, could be the first marketed CD47-targeting therapy and can generate peak sales of C$1.4B for hematologic and solid tumors.
AXAS Abraxas Petroleum
$2.36

0.04 (1.72%)

08/11/17
GHSC
08/11/17
UPGRADE
GHSC
Buy
Abraxas Petroleum upgraded to Buy from Neutral at Seaport Global
Seaport Global analyst Mike Kelly upgraded Abraxas Petroleum to Buy and raised its price target to $2.50 from $2 to reflect relative share underperformance, "fantastic progress" in the Delaware, and "very bullish" projections through 2019.
12/19/17
BARD
12/19/17
UPGRADE
BARD
Outperform
Abraxas Petroleum assumed with Outperform from Neutral at Baird
Baird analyst Joseph Allman assumed coverage on Abraxas Petroleum with an Outperform versus the firm's prior Neutral rating. Allman has a $3 price target on Abraxas Petroleum shares.
07/24/17
ADAM
07/24/17
INITIATION
Target $2.5
ADAM
Buy
Abraxas Petroleum initiated with a Buy at Canaccord
Canaccord Genuity analyst Sam Roach started Abraxas Petroleum with a Buy rating and $2.50 price target. The company is creating shareholder value despite low oil prices by de-risking assets, growing net asset value and improving well design, the analyst contends.
06/21/17
GHSC
06/21/17
DOWNGRADE
GHSC
Neutral
Abraxas Petroleum downgraded to Neutral from Buy at Seaport Global
SIEN Sientra
$10.03

-0.35 (-3.37%)

01/19/18
STFL
01/19/18
UPGRADE
STFL
Buy
Sientra upgraded to Buy from Hold at Stifel
01/19/18
01/19/18
UPGRADE
Target $14

Buy
Sientra upgraded to Buy at Stifel
As previously reported, Stifel analyst Johnathan Block upgraded Sientra to Buy from Hold, stating that his September checks showed likely market share gains upon full resumption of manufacturing. Doctor feedback from miraDry users indicate that results appear efficacious and patient volumes are expected to increase, Block added. The analyst, who also pointed to easy year-ago comps in the second half for both of the company's businesses, set a $14 price target on Sientra shares. However, he did note that the upgrade may be coming before Sientra may end up raising additional capital in the near-term.
09/13/17
WBLR
09/13/17
UPGRADE
WBLR
Outperform
Sientra upgraded to Outperform from Market Perform at William Blair
William Blair analyst Margaret Kaczor upgraded Sientra to Outperform saying the manufacturing approval is "just the tip of the story."
02/21/18
LSCM
02/21/18
DOWNGRADE
Target $11
LSCM
Hold
Sientra downgraded to Hold from Buy at Lake Street
Lake Street analyst Brooks O'Neil downgraded Sientra to Hold and lowered his price target for the shares to $11 from $15. The company is "attempting to walk a fine line" with the at-the-market equity offering announced last night, O'Neil tells investors in a research note. The analyst does not sense there is a new delay related to securing FDA approval for silicone breast implant manufacturing with Vesta, but thinks near-term cash consumption, execution, and dilution risks may act as an overhang on the stock.
SILC Silicom
$40.66

-17.9 (-30.57%)

01/12/18
NEED
01/12/18
NO CHANGE
Target $90
NEED
Buy
Silicom price target raised to $90 from $75 at Needham
Needham analyst Alex Henderson raised his price target on Silicom to $90, citing strong ramp and lengthening visibility from the company's deals signed over the past year. The analyst says the booked deals could double the size of the company over the next two years as they ramp to full production in that time span. Henderson keeps his Buy rating on Silicom.
04/27/17
04/27/17
NO CHANGE

Silicom reports Q1 non-GAAP EPS 52c, consensus 48c
Reports Q1 revenue $25.3M, consensus $23.86M.
07/25/17
NEED
07/25/17
NO CHANGE
Target $67
NEED
Buy
Silicom price target raised to $67 from $60 at Needham
Needham analyst Alex Henderson raised his price target for Silicom to $67 from $60 saying the company is at an inflection point where numerous demand drivers are poised to drive significantly higher rates of growth. The analyst reiterates a Buy rating on the shares.
CTT CatchMark Timber
$13.61

-0.03 (-0.22%)

TNTR Tintri
$4.35

-0.41 (-8.61%)

09/20/17
09/20/17
DOWNGRADE

Underperform
Tintri downgraded to Underperform at Raymond James
As previously reported, Raymond James downgraded Tintri to Underperform from Outperform. Analyst Simon Leopold said the weak share price will make employee retention challenging and the potential loss of key staff increases risks in achieving financial targets.
12/14/17
KEYB
12/14/17
DOWNGRADE
KEYB
Sector Weight
Tintri downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Alex Kurtz downgraded Tintri to Sector Weight citing continued sales challenges following the company's Q3 results. The analyst sees "multiple headwinds," including apparent concerns from end-customers related to Tintri's cash position.
12/14/17
BOFA
12/14/17
DOWNGRADE
Target $5
BOFA
Underperform
Tintri downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Wamsi Mohan downgraded Tintri to Underperform and lowered its price target to $5 from $7 following the Q3 miss and "disappointing" guidance. Mohan significantly lowered his revenue estimates and is taking a more cautious view on a revenue recovery.
09/21/17
NEED
09/21/17
DOWNGRADE
NEED
Hold
Tintri downgraded to Hold from Buy at Needham
RPD Rapid7
$27.52

0.31 (1.14%)

01/30/18
KEYB
01/30/18
NO CHANGE
Target $30
KEYB
Overweight
Rapid7 price target raised to $30 from $35 at KeyBanc
KeyBanc analyst Rob Owens raised his price target for Rapid7 to $30 from $25 after incorporating raised guidance for Q4. The analyst reiterates an Overweight rating on the shares.
10/23/17
NEED
10/23/17
INITIATION
Target $23
NEED
Buy
Rapid7 initiated with a Buy at Needham
Needham analyst Alex Henderson initiated Rapid7 with a Buy and $23 price target.
02/28/18
STFL
02/28/18
INITIATION
Target $32
STFL
Buy
Rapid7 initiated with a Buy at Stifel
Stifel analyst Gur Talpaz started Rapid7 with a Buy rating and $32 price target. The analyst believes the company can sustain 30%-plus annualized recurring revenue growth through 2020. Talpaz views Rapid7 as one of the "key players within the fast growing" vulnerability assessment marketplace.
08/08/17
SUSQ
08/08/17
UPGRADE
Target $20
SUSQ
Positive
Rapid7 upgraded to Positive at Susquehanna
As previously reported, Susquehanna analyst Anne Meisner upgraded Rapid7 to Positive from Neutral on the heels of a solid quarter and a sharp pullback in the shares over the past two months. She notes the company continues its shift to a subscription model and she sees strong mid-market security spending trends. Meisner maintained her $20 price target on Rapid7 shares.
HGV Hilton Grand Vacations
$45.80

-0.27 (-0.59%)

06/16/17
RHCO
06/16/17
NO CHANGE
RHCO
ILG 'deal could make sense but timing uncertain,' says SunTrust
After Reuters reported that ILG (ILG) has hired bankers to pursue a merger and held talks with Marriott Vacations (VAC) and Hilton Grand Vacations (HGV) about a deal, SunTrust analyst C. Patrick Scholes says that Marriott Vacations would have the most cost synergies with ILG, while Hilton Grand Vacations "would be an odd fit," partly because its cost synergies would be much lower than those of Marriott, while it licenses its brand from a different company than ILG. Scholes notes that time share multiples are high from a historical perspective, and he says that ILG's acquisition of Vistana 13 months ago may have included a provision which would prevent ILG from selling itself until May 2018. The analyst says that an acquisition of ILG "could make sense," but he thinks that the timing of any deal is "uncertain." Scholes keeps a $26 price target and a Buy rating on the stock.
06/19/17
BUCK
06/19/17
INITIATION
Target $42
BUCK
Buy
Hilton Grand Vacations initiated with a Buy at Buckingham
Buckingham analyst Christopher Jones initiated Hilton Grand Vacations (HGV) with a Buy and a $42 price target saying the Hilton (HLT) relationship supports overall revenue and contact sales growth and has over $600M in capital waiting to be deployed.
10/05/17
RHCO
10/05/17
NO CHANGE
RHCO
Hilton Grand Vacations, ILG combination unlikely, says SunTrust
After Bloomberg reported on a possible bid for ILG (ILG) by Marriott Vacations (VAC), SunTrust analyst Bradford Dalinka does not believe that a combination of Hilton Grand Vacations (HGV) and ILG (ILG) would make sense. The analyst says that "there is a unique synergy opportunity" between ILG and Marriott Vacations. He remains upbeat on Hilton Grand's fundamentals and keeps a $41 price target and a Buy rating on the shares.
01/05/18
MACQ
01/05/18
INITIATION
Target $47
MACQ
Neutral
Hilton Grand Vacations initiated with a Neutral at Macquarie
Macquarie analyst Edward Engel initiated Hilton Grand Vacations with a Neutral and $47 price target due to limited operating leverage.

TODAY'S FREE FLY STORIES

COR

CoreSite Realty

$97.28

-2 (-2.01%)

, DLR

Digital Realty

$115.80

-1.135 (-0.97%)

05:53
12/10/18
12/10
05:53
12/10/18
05:53
Downgrade
CoreSite Realty, Digital Realty, Equinix rating change  »

CoreSite Realty…

COR

CoreSite Realty

$97.28

-2 (-2.01%)

DLR

Digital Realty

$115.80

-1.135 (-0.97%)

EQIX

Equinix

$386.76

-6.1 (-1.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

APDN

Applied DNA Sciences

$1.08

0.02 (1.89%)

05:52
12/10/18
12/10
05:52
12/10/18
05:52
Hot Stocks
Applied DNA Sciences signs joint development agreement with Everledger »

Applied DNA Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

EQIX

Equinix

$386.76

-6.1 (-1.55%)

05:51
12/10/18
12/10
05:51
12/10/18
05:51
Upgrade
Equinix rating change  »

Equinix upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

DLR

Digital Realty

$115.80

-1.135 (-0.97%)

05:50
12/10/18
12/10
05:50
12/10/18
05:50
Upgrade
Digital Realty rating change  »

Digital Realty upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RSAIF

RSA Insurance

$0.00

(0.00%)

05:47
12/10/18
12/10
05:47
12/10/18
05:47
Upgrade
RSA Insurance rating change  »

RSA Insurance upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWDHF

Skyworth Digital

$0.00

(0.00%)

05:45
12/10/18
12/10
05:45
12/10/18
05:45
Downgrade
Skyworth Digital rating change  »

Skyworth Digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$40.72

-2.17 (-5.06%)

05:44
12/10/18
12/10
05:44
12/10/18
05:44
Hot Stocks
Biohaven announces initial 'positive' results from ongoing rimegepant study »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSRO

Tesaro

$73.87

0.1 (0.14%)

, GSK

GlaxoSmithKline

$37.28

-0.125 (-0.33%)

05:42
12/10/18
12/10
05:42
12/10/18
05:42
Downgrade
Tesaro, GlaxoSmithKline rating change  »

Tesaro downgraded to…

TSRO

Tesaro

$73.87

0.1 (0.14%)

GSK

GlaxoSmithKline

$37.28

-0.125 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWARF

Norwegian Air Shuttle

$0.00

(0.00%)

05:40
12/10/18
12/10
05:40
12/10/18
05:40
Upgrade
Norwegian Air Shuttle rating change  »

Norwegian Air Shuttle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASX

ASE Technology

$3.77

-0.06 (-1.57%)

05:39
12/10/18
12/10
05:39
12/10/18
05:39
Earnings
ASE Technology reports November revenue down 3.2% to $1.23B »

Reports November IC-atm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$18.42

0.41 (2.28%)

05:38
12/10/18
12/10
05:38
12/10/18
05:38
Periodicals
Rice Energy brothers want to take over running EQT, WSJ reports »

Derek and Toby Rice, who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

ALNY

Alnylam

$74.28

-5.45 (-6.84%)

05:37
12/10/18
12/10
05:37
12/10/18
05:37
Hot Stocks
Alnylam announces settlement with Silence Therapeutics »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$53.08

-0.16 (-0.30%)

05:36
12/10/18
12/10
05:36
12/10/18
05:36
Hot Stocks
Bristol-Myers enters new clinical collaboration with Vedanta Biosciences »

Bristol-Myers and Vedanta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Dec

  • 24

    Jan

  • 20

    May

QDEL

Quidel

$48.48

-12.835 (-20.93%)

05:35
12/10/18
12/10
05:35
12/10/18
05:35
Conference/Events
Quidel to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

IQ

iQIYI

$18.51

-1.34 (-6.75%)

, CHL

China Mobile

$49.28

0.61 (1.25%)

05:34
12/10/18
12/10
05:34
12/10/18
05:34
Hot Stocks
iQIYI signs partnership with China Mobile »

iQIYI (IQ) recently…

IQ

iQIYI

$18.51

-1.34 (-6.75%)

CHL

China Mobile

$49.28

0.61 (1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QDEL

Quidel

$48.48

-12.835 (-20.93%)

05:27
12/10/18
12/10
05:27
12/10/18
05:27
Recommendations
Quidel analyst commentary  »

Quidel shares likely flat…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

05:24
12/10/18
12/10
05:24
12/10/18
05:24
Hot Stocks
Roche CEO Daniel O'Day to step down, Genentech CEO William Anderson to succeed »

Roche (RHHBY) announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 24

    Dec

  • 18

    Mar

EA

Electronic Arts

$82.57

-1.29 (-1.54%)

05:22
12/10/18
12/10
05:22
12/10/18
05:22
Recommendations
Electronic Arts analyst commentary  »

Electronic Arts price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$68.17

-2.01 (-2.86%)

, RHHBY

Roche

$0.00

(0.00%)

05:21
12/10/18
12/10
05:21
12/10/18
05:21
Hot Stocks
Gilead appoints Roche CEO Daniel O'Day as CEO, chairman »

Gilead Sciences announced…

GILD

Gilead

$68.17

-2.01 (-2.86%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 24

    Dec

  • 18

    Mar

FIVE

Five Below

$95.53

-6.19 (-6.09%)

05:16
12/10/18
12/10
05:16
12/10/18
05:16
Upgrade
Five Below rating change  »

Five Below upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMXAY

Genmab

$0.00

(0.00%)

05:12
12/10/18
12/10
05:12
12/10/18
05:12
Upgrade
Genmab rating change  »

Genmab upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCBJY

UCB

$0.00

(0.00%)

05:10
12/10/18
12/10
05:10
12/10/18
05:10
Upgrade
UCB rating change  »

UCB upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWTUY

Swedish Orphan Biovitrum

$0.00

(0.00%)

05:08
12/10/18
12/10
05:08
12/10/18
05:08
Upgrade
Swedish Orphan Biovitrum rating change  »

Swedish Orphan Biovitrum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOR

MorphoSys

$27.63

-0.105 (-0.38%)

, JNJ

Johnson & Johnson

$145.38

-0.52 (-0.36%)

05:06
12/10/18
12/10
05:06
12/10/18
05:06
Upgrade
MorphoSys, Johnson & Johnson rating change  »

MorphoSys upgraded to Buy…

MOR

MorphoSys

$27.63

-0.105 (-0.38%)

JNJ

Johnson & Johnson

$145.38

-0.52 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

SLG

SL Green Realty

$93.32

-2.41 (-2.52%)

05:02
12/10/18
12/10
05:02
12/10/18
05:02
Upgrade
SL Green Realty rating change  »

SL Green Realty upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.